Thromb Haemost 1994; 72(06): 931-936
DOI: 10.1055/s-0038-1648986
Original Article
Schattauer GmbH Stuttgart

Detection of Plasminogen Activator Inhibitor-1 (PAI-1) mRNA in Human Megakaryocytes by In Situ Hybridization

M C Alessi
The Laboratory of Hematology, CHU Timone, Marseille, France
,
N Chomiki
The Laboratory of Hematology, CHU Timone, Marseille, France
,
R Berthier
The Laboratory of Hematology, CHU Timone, Marseille, France
,
A Schweitzer
1   Unité de Recherche sur I’Hémostase Cellulaire et Moléculaire, INSERM 217, Grenoble, France
,
C Fossat
1   Unité de Recherche sur I’Hémostase Cellulaire et Moléculaire, INSERM 217, Grenoble, France
,
I Juhan-Vague
The Laboratory of Hematology, CHU Timone, Marseille, France
› Author Affiliations
Further Information

Publication History

Received 12 April 1994

Accepted after resubmission 11 August 1994

Publication Date:
06 July 2018 (online)

Summary

Platelets have been described to contain a large proportion of the circulating plasminogen activator inhibitor type 1 (PAI-1) which is released on platelet activation. This protein could be taken up by platelets from the plasma or synthesized by megakaryocytes (MKs). Recently, PAI-1 mRNA has been detected in a human megakaryoblastic leukemia cell line (MEG-01) by the polymerase chain reaction (PCR). However, a direct demonstration of its presence in normal human MKs is lacking.

In order to prove directly the megakaryocytic origin of platelet PAI-1, the MEG-01 cell line, human bone marrow enriched in MKs, and bone marrow smears from allogeneic bone marrow transplantation donors were investigated for the presence of PAI-1 mRNA using in situ hybridization (ISH). Specimens of bone marrow were first stained with May-Grunwald Giemsa (MGG) for cell identification according to their morphology. Subsequently, the same slides were used for ISH. PAI-1 mRNA was clearly demonstrated in the MEG-01 cell line and in MKs, and its presence correlated with the detection of PAI-1 antigen by immunocytochemistry. PAI-1 mRNA was also detected in morphologically characterized mature granulocytes of marrow samples.

 
  • References

  • 1 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
  • 2 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-1472
  • 3 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-333
  • 4 Kruithof EKO, Tran-Thang C, Bachmann F. Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost 1986; 55: 201-205
  • 5 Sprengers ED, Akkerman JWN, Jansen BG. Blood platelet plasminogen activator inhibitor: Two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost 1986; 55: 325-329
  • 6 George JN. Platelet immunoglobulin G. Its significance for the evaluation of thrombocytopenia and for understanding the origin of a-granule proteins. Blood 1990; 76: 859-870
  • 7 Konkle BA, Schick PK, He X, Liu RJ, Mazur EM. Plasminogen activator inhibitor 1 mRNA is expressed in platelets and megakaryocytes and the mega-karyoblastic cell line CHRF-288. Arterioscler Thromb 1993; 13: 669-674
  • 8 Perez GN, Nelles L, Deckmyn H, Vermylen J. PAI-1 is not synthetized in human platelets. Thromb Haemost 1993; 215: 719
  • 9 Sottile J, Mosher DF, Fullenweider J, George JN. Human platelets contain mRNA transcripts for platelet factor 4 and actin. Thromb Haemost 1989; 62: 1100-1105
  • 10 Spom LA, Chavin I, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 1985; 76: 1102-1106
  • 11 Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1990; 44: 139-143
  • 12 Alford CT, Bennett B, Booth NA. Plasminogen activator inhibitors in isolated human megakaryocytes and in a megakaryoblastic cell line (MEG-01). Blood Coagulat Fibrinol 1993; 4: 367
  • 13 Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, Nagura H, Saito H. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01 with positive Philadelphia chromosome. Blood 1985; 66: 1384-1392
  • 14 Berthier R, Valiron O, Schweitzer A, Marguerie G. Serum-free medium allows the optimal growth of human megakaryocyte progenitors compared with human plasma supplemented cultures. Role of TGF β. Stem Cells 1993; 11: 120-129
  • 15 Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Dano K, Lebo RV, Gelehrter TD. cDNA cloning of human plasminogenactivator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673-1680
  • 16 Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Nad Acad Sci USA 1985; 82: 6394-6398
  • 17 Melton DA, Krieg PA, Rebegliati MR, Maniatis T, Zinn K, Green MR. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucl Acid Res 1984; 12: 7035-7056
  • 18 Holtke HJ, Kessler C. Non-radioactive labeling of RNA transcripts in vitro with the hapten digoxigenin (DIG); hybridization and ELISA based detection. Nucl Acid Res 1990; 18: 5843-5851
  • 19 Brisson-Jeanneau C, Nelles L, Rover E, Sultan Y, Benarous R. Tissue-plasmin-ogen activatorRNA detected in megakaryocytes byin situ hybridization and biotinylated probe. Histochemistry 1990; 95: 23-26
  • 20 Jeanneau C, Sultan Y. Tissue-plasminogen activator in human megakaryocytes and platelets: Immunocytochemical localization, immunoblotting and zymo-graphic analysis. Thromb Haemost 1988; 59: 529-534
  • 21 Vinci G, Tabilio A, Deschamps JF, Van Hacke D, Henri A, Guichard J, Tetteroo P, Lansdorp PM, Hercend T, Vainchenker W, Breton-Gorius J. Immunological study of in vitro maturation of human megakaryocytes. Br J Haematol 1984; 56: 589-605
  • 22 Courtney MA, Stoler MH, Marder VJ, Haidaris PJ. Developmental expression of mRNAs encoding platelet proteins in rat megakaryocytes. Blood 1991; 77: 560-568
  • 23 Krishnamurti C, Barr CF, Hassett MA, Young GD, Alving BM. Plasminogen activator inhibitor: A regulator of ancrod induced fibrin deposition in rabbits. Blood 1987; 69: 798-803
  • 24 Barbash GI, Hod H, Roth A, Miller HI, Rath S, Harzahav Y, Modan M, Zivelin A, Laniado S, Seligsohn U. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989; 64: 1231-1235
  • 25 Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Reactively recombinant plasminogen activator inhibitor 1 (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemost 1992; 68: 60-63
  • 26 Reilly CF, Fujita T, Hutzelmann JE, Mayer EJ, Shebuski RJ. Plasminogen activator inhibitor 1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism. Circulation 1991; 84: 287-292
  • 27 Simpson AJ, Booth NA, Moore NR, Bennett B. The platelet and plasma pools of plasminogen activator inhibitor (PAI-1) vary independently in disease. Br J Haematol 1990; 75: 543-547